Company intelligence / Profile preview

21st.BIO

Copenhagen / Virum, Denmark21st.bio ↗

Ownership: Private
Development stage: Commercial

Overview

21st.BIO provides end-to-end precision fermentation solutions to help companies scale up the production of recombinant proteins and peptides for use in food, nutrition, agriculture, biomaterials, and related industries. The company offers strain development, process optimization, pilot plant capabilities (over 3000L), tech transfer to large-scale manufacturing, and regulatory support. Its technology is partly licensed from Novonesis (formerly Novozymes), leveraging decades of expertise in industrial enzyme/protein production.

Modalities: Recombinant proteinPeptides
Industry: Non-Drug Biotech

Partnerships

Novonesis/Novozymes (technology licensing)

Beyond the preview

Go deeper on 21st.BIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 21st.BIO.

Explore the full profile